Results 171 to 180 of about 64,512 (289)

Opportunities in cancer gene therapy: inhibiting MDM2 and restoring p14ARF as a means to activate p53. [PDF]

Mol Cell Biochem
de Oliveira SB, Alves ALV, Niitsuma BN, Antunes F, Marinho GB, Amanatidis GL, Luz J, Barbosa M, Zambotti PEO, Rodrigues OA, Strauss BE.   +10 more
europepmc   +1 more source

USP25 promotes ferroptosis in diabetic retinopathy by deubiquitinating p53 and suppressing the GPX4/SLC7A11 axis

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Objective To explore the expression of the deubiquitinase (DUB) USP25 in diabetic retinopathy (DR) and its mechanistic role in regulating ferroptosis. Methods Bioinformatics was used to screen for DR‐related DUB candidate genes. USP25 expression was validated in a streptozotocin‐induced diabetic mouse model and high glucose (HG)‐treated ARPE ...
Yanjun Gao, Wenjing Zhao, Qiannan Chai, Cunxi Ye   +3 more
wiley   +1 more source

Case Report WIN-MTB-2024001 - WIN International Molecular Tumor Board: A 55-year-old male with glioblastoma exhibiting amplifications in MDM2 and EGFR. [PDF]

Oncotarget
El-Deiry WS, Ikeda S, Magidi S, Bresson C, Abdel-Razeq H, Joshua A, Hernando-Calvo A, Oberoi A, Hu Z, Meissner T, Elsey R, Al-Omari A, Wunder F, Kurzrock R.   +13 more
europepmc   +1 more source

Senolytics and exercise: Dual modalities for rejuvenating muscle

The Journal of Physiology, EarlyView.
Abstract figure legend The role of senolytics on the heart and skeletal muscle. Senescent cell burden increases with ageing, disuse and disease. The senolytics dasatinib+quercetin (D+Q), navitoclax and fisetin, as well as exercise, eliminate senescent cells, reducing senescent cell burden and their senescence‐associated secretory phenotype (SASP ...
Zeynep Elif Yesilyurt‐Dirican, Ce Qi, Uchenna Okpechi, Maya Strand Ford, Georgina M. Ellison‐Hughes   +4 more
wiley   +1 more source

Brightline-1: When a Negative Trial Reveals Two Active Therapies. [PDF]

Clin Cancer Res
Shahnam A, Gounder MM.
europepmc   +1 more source

microRNA‐145‐5p regulates P‐glycoprotein and breast cancer resistance protein in primary human fetal brain endothelial cells

The Journal of Physiology, EarlyView.
Abstract figure legend Drug transporters P‐glycoprotein (P‐gp) and breast cancer resistance protein (BCRP) at the blood–brain barrier (BBB) protect the rapidly developing fetal brain. We investigated the role of microRNA‐145‐5p (miR‐145‐5p) microRNA (miRNA) in regulating these key transporters in primary human fetal brain endothelial cells in vitro. We
Phetcharawan Lye, Enrrico Bloise, Nikola Ivanovski, Lubna Nadeem, Christopher Casciaro, Stephen G. Matthews   +5 more
wiley   +1 more source

Association of MDM2 rs2279744 and rs937282 polymorphisms with breast cancer susceptibility and circulating MDM2 and p53 levels in Bangladeshi women: A case-control study. [PDF]

PLoS One
Chowdhury MH, Islam F, Khan AA, Siddique MA, Hasan NB, Samrat MI, Tanisha MH, Tasnim J, Mahjabin S, Islam MN, Haque MA.   +10 more
europepmc   +1 more source

Cancer‐associated fibroblast heterogeneity across solid and haematological malignancies: Lessons from colorectal cancer and multiple myeloma

The Journal of Physiology, EarlyView.
Abstract figure legend CAF origins and plasticity give rise to distinct phenotypes with immunosuppressive functions in colorectal cancer and multiple myeloma. These distinct CAF phenotypes contribute to immunosuppressive tumour microenvironments through ECM remodelling, cytokine signalling and immune regulation.
Hui Mo, Haoyan Han, Michael O'Dwyer, Eileen Reidy, Aideen E. Ryan   +4 more
wiley   +1 more source

Superactivation of p53 Using Drug Combinations and New Insights into p53 Functions and Anticancer Therapy. [PDF]

Int J Mol Sci
Rusin M, Krześniak M, Łasut-Szyszka B.
europepmc   +1 more source

Impact of Molecular Alterations on Survival in Biliary Tract Cancers: A Retrospective Belgian Cohort Study

International Journal of Cancer, Volume 160, Issue 1, Page 201-215, 1 January 2027.
ABSTRACT Biliary tract cancers (BTCs) are aggressive malignancies associated with a poor prognosis. Although molecular profiling is recommended to guide therapeutic decision‐making, real‐practice data on the prevalence and prognostic significance of genomic alterations in European BTC cohorts remain limited.
Jorine Arnouts, Léon C. van Kempen, Senada Koljenović, Helena Oliveres, Pieterjan Vanclooster, Hans Prenen, Caro De Weerdt, Siddharth Chhajlani, Geert Roeyen, Laure Sorber, Koen De Winne, Jonas Dahnoun, Greetje Vanhoutte, Timon Vandamme, Karen Zwaenepoel   +14 more
wiley   +1 more source